ELAN — Elanco Animal Health Incorporated stock price, charts and financials
QT80Elanco Animal Health IncorporatedElanco Animal Health Incorporated (NYSE: ELAN) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.49 | Insider Own | 1.13% | Shs Outstand | 499.45M | Perf Week | 5.86% |
| Market Cap | 13.18B | Forward P/E | 21.99 | EPS next Y | 1.20 | Insider Trans | 0.17% | Shs Float | 494.82M | Perf Month | 9.46% |
| Enterprise Value | 16.74B | PEG | 0.34 | EPS next Q | - | Inst Own | - | Short Float | 7.24% | Perf Quarter | 17.88% |
| Income | -242.52M | P/S | 2.69 | EPS this Y | 317.43% | Inst Trans | - | Short Ratio | 6.23 | Perf Half Y | 8.97% |
| Sales | 4.89B | P/B | 2.02 | EPS next Y | 12.54% | ROA | -1.83% | Short Interest | 35.82M | Perf YTD | 16.53% |
| Book/sh | - | P/C | 22.76 | EPS next 5Y | 9.56% | ROE | -3.64% | 52W High | 27.04 -4.87% | Perf Year | 86.76% |
| Cash/sh | - | P/FCF | 41.84 | EPS past 3/5Y | - | ROIC | 3.77% | 52W Low | 13.06 96.94% | Perf 3Y | 116.50% |
| Dividend Est. | - | EV/EBITDA | 21.92 | Sales past 3/5Y | 2.25% 7.57% | Gross Margin | 49.44% | Volatility | 2.94% 3.33% | Perf 5Y | -27.75% |
| Dividend TTM | - | EV/Sales | 3.42 | EPS Y/Y TTM | -172.06% | Oper. Margin | 8.95% | ATR (14) | 0.88 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.12 | Sales Y/Y TTM | 10.23% | Profit Margin | -4.95% | RSI (14) | 63.11 | Recom | 2.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.16 | EPS Q/Q | 8.11% | SMA20 | 3.88% | Beta | 1.66 | Target Price | 28.33 |
| Payout | 0.00% | Debt/Eq | 0.61 | Sales Q/Q | 14.92% | SMA50 | 8.08% | Rel Volume | 0.88 | Prev Close | 26.37 |
| Employees | 9,900 | LT Debt/Eq | 0.60 | Earnings | Aug 05 | SMA200 | 12.43% | Avg Volume | 5.89M | Price | 25.72 |
| IPO Date | Sep 20, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 15.75% 7.35% | Net Debt/EBITDA | 4.66 | Volume | 5,193,836 | Change | -2.46% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-22-26 | Reiterated | Morgan Stanley | Equal Weight | $23 → $26 |
| May-15-26 | Reiterated | Morgan Stanley | Equal Weight | $24 → $23 |
| Feb-25-26 | Reiterated | Keybanc | Overweight | $27 → $29 |
| Feb-24-26 | Reiterated | Leerink Partners | Outperform | $18 → $30 |
| Jan-29-26 | Reiterated | UBS | Buy | $27 → $30 |
| Jan-22-26 | Upgrade | Piper Sandler | Neutral → Overweight | $12 → $30 |
| Dec-18-25 | Reiterated | Morgan Stanley | Equal Weight | $37 → $22 |
| Dec-08-25 | Initiated | Barclays | Overweight | $22 → $30 |
| Nov-20-25 | Initiated | KeyBanc | Overweight | $27 |
| Nov-19-25 | Reiterated | Argus Research | Buy | $25 |
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,893 | 4,715 | 4,439 | 4,417 | 4,411 | 4,764 | 3,273 | 3,071 | 3,067 | |
| Cost of Goods Sold Incl. D&A | 2,474 | 2,665 | 2,530 | 2,479 | 2,441 | 2,688 | 2,027 | 1,671 | 1,771 | |
| Gross Profit | 2,419 | 2,050 | 1,909 | 1,938 | 1,970 | 2,076 | 1,247 | 1,400 | 1,296 | |
| Selling, General and Administrative Excl. Other | 1,470 | 1,430 | 1,314 | 1,285 | 1,265 | 1,403 | 997 | 760 | 735 | |
| Research and Development | 371 | 368 | 344 | 327 | 321 | 369 | 327 | 270 | 247 | |
| Other Operating Expense | 140 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating Income | 438 | 252 | 251 | 326 | 384 | 304 | -77 | 370 | 314 | |
| Interest Expense | 270 | 220 | 339 | 277 | 256 | 264 | 156 | 79 | 30 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -365 | -256 | 576 | -1,244 | -200 | -611 | -439 | -213 | -170 | |
| Net Income Before Taxes | -197 | -224 | 488 | -1,195 | -72 | -571 | -672 | 78 | 114 | |
| Income Taxes | 45 | 8 | 150 | 36 | 6 | -88 | -112 | 10 | 28 | |
| Consolidated Net Income | -242 | -232 | 338 | -1,231 | -78 | -483 | -560 | 68 | 87 | |
| Net Income From Continuing Operations | -242 | -232 | 338 | -1,231 | -78 | -483 | -560 | 68 | 87 | |
| Net Income | -242 | -232 | 338 | -1,231 | -78 | -483 | -560 | 68 | 87 | |
| EPS (Recurring) | -0.50 | -0.47 | 0.68 | -2.50 | -0.15 | -0.97 | -1.27 | 0.18 | 0.28 | |
| EPS (Basic, Before Extraordinaries) | -0.50 | -0.47 | 0.68 | -2.50 | -0.15 | -0.97 | -1.27 | 0.18 | 0.28 | |
| EPS (Diluted) | -0.49 | -0.47 | 0.68 | -2.50 | -0.15 | -0.97 | -1.27 | 0.18 | 0.28 | |
| EBITDA | 764 | 676 | 1,489 | -224 | 866 | 409 | 1 | 472 | 440 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 17.81 | — | — | — | — | 163.61 | 112.61 | |
| Price To Sales Ratio | 2.62 | 2.38 | 1.35 | 1.66 | 1.35 | 2.90 | 4.13 | 3.54 | 3.23 | |
| Gross Margin | 49.44 | 43.48 | 43.01 | 43.88 | 44.66 | 43.58 | 38.10 | 45.59 | 42.26 | |
| Operating Margin | 8.95 | 5.34 | 5.65 | 7.38 | 8.71 | 6.38 | -2.35 | 12.05 | 10.24 | |
| Net Margin | -4.95 | -4.92 | 7.61 | -27.87 | -1.77 | -10.14 | -17.11 | 2.21 | 2.84 | |
| Shares Outstanding | 498 | 496 | 494 | 492 | 488 | 487 | 441 | 369 | 314 | |
| Market Capitalization | 12,809 | 11,224 | 5,982 | 7,331 | 5,963 | 13,821 | 13,525 | 10,867 | 9,900 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Modi Rajeev A. | SEE REMARKS | May 15 '26 | Buy | 20.35 | 4,911 | 99,939 | 160,812 | May 19 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR | May 15 '26 | Buy | 20.09 | 4,971 | 99,843 | 171,971 | May 19 |
| Kurzius Lawrence Erik | Director | Dec 12 '25 | Buy | 21.30 | 10,000 | 213,000 | 131,773 | Dec 16 |
| Modi Rajeev A. | SEE REMARKS | Dec 11 '25 | Buy | 21.33 | 4,500 | 95,985 | 123,082 | Dec 15 |
| VanHimbergen Robert M | EVP and CFO | Dec 11 '25 | Buy | 21.64 | 6,950 | 150,426 | 124,233 | Dec 15 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR | Dec 11 '25 | Buy | 21.75 | 22,000 | 478,496 | 167,000 | Dec 15 |
| Kurzius Lawrence Erik | Director | Mar 11 '25 | Buy | 10.20 | 10,000 | 102,000 | 111,459 | Mar 11 |
| Kurzius Lawrence Erik | Director | Mar 07 '25 | Buy | 10.90 | 10,000 | 109,000 | 101,459 | Mar 11 |
| HOOVER R DAVID | Director | Mar 05 '25 | Buy | 10.90 | 25,000 | 272,558 | 210,000 | Mar 07 |